Acro Biomedical Co Ltd Financials

Acro Biomedical Co Ltd (ACBM) reported $0 in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

No, Acro Biomedical Co Ltd (ACBM) reported a net income of -$101K in fiscal year 2025.

Acro Biomedical Co Ltd (ACBM) reported diluted earnings per share of $0.00 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Acro Biomedical Co Ltd (ACBM) generated -$196K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

Acro Biomedical Co Ltd (ACBM) had $14K in total assets as of fiscal year 2025, including both current and long-term assets.

Acro Biomedical Co Ltd (ACBM) had 60M shares outstanding as of fiscal year 2025.

Acro Biomedical Co Ltd (ACBM) had a current ratio of 0.04 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.

Acro Biomedical Co Ltd (ACBM) had a debt-to-equity ratio of -1.04 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

Acro Biomedical Co Ltd (ACBM) had a return on assets of -717.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Based on fiscal year 2025 data, Acro Biomedical Co Ltd (ACBM) had $4K in cash against an annual operating cash burn of $196K. This gives an estimated cash runway of approximately 0 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

Acro Biomedical Co Ltd (ACBM) has negative shareholder equity of -$387K as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

Acro Biomedical Co Ltd (ACBM) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Acro Biomedical Co Ltd (ACBM) has an earnings quality ratio of 1.94x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.